Acadia Pharma (ACAD) Tops Q1 EPS by 11c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $27.58 -1.57%
EPS Growth %: -52.4%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -52.4%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.42), $0.11 better than the analyst estimate of ($0.53). Revenue for the quarter came in at $106.6 million versus the consensus estimate of $111.63 million.
Reiterating FY21 net sales guidance of $510 to $550 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
- BMO Capital Starts American Eagle Outfitters (AEO) at Market Perform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
